Mitsu Chem Plast Ltd Q1 FY2024 Concall Summary

Key Takeaways

• Margin floor called, recovery promised: Q1 delivered historically low margins, but management declared this the bottom and guided to at least 10% EBITDA this year, with improvement starting Q2 as cheaper raw material flows through.
• Raw material is the whole story: 60% of inputs are imported, 40% of that is a compulsory grade India does not make, forcing 75-90 days of inventory and exposing the company to a price cycle it cannot hedge.
• Revenue stuck in a band: Topline has been stagnant in the ₹70-80 crore range for six quarters; management expects a breakout from new products and exports but offered no quantified timeline.
• The unorganized-sector gap is widening: BIS, EPR and compliance costs are rising while unorganized competitors ignore them, making price hikes harder to pass on to customers whose own margins are shrinking.
• What to watch next quarter: Whether the raw material cost benefit actually lifts EBITDA margins off the Q1 floor, and whether any of the promised new products or export orders materialize into revenue.

Margin Pressure & the Raw Material Trap

• Import dependency is structural: 60% of raw material is imported, and 40% of that total is a compulsory grade not manufactured in India, forcing the company to hold 75-90 days of inventory and absorb the gap between local and import prices.
• No hedge available: Plastic raw material prices move both up and down, and hedging instruments do not exist for the category, leaving the company fully exposed to the cycle.
• The pass-through squeeze: Some competitors sell at lower prices for reasons management says it does not understand; the company sometimes walks away from business or passes on benefits, but raising prices when costs rise is "really, really difficult" because customers in chemicals and pharma have shrunk their own margins.
• Compliance costs add to the burden: BIS, EPR and other regulatory requirements have added costs that unorganized players do not bear, widening the competitive disadvantage.
• The Q2 relief thesis: Raw material prices softened from May and June onward; material booked at those lower prices arrived in July and August, so the cost benefit should show in Q2 margins.

Dedhia: "Your observation is very, very correct and I do not think so, we do not wish to also go below that. I think this is the bottom now we cannot go below this."

Revenue Trajectory & Growth Bets

• Six quarters of stagnation: Revenue has been range-bound at ₹70-80 crore; management is planning developments to improve both turnover and profitability and says FY24 will be "much better than last year."
• New customer additions: Around 25 customers were added in the last quarter, though the revenue contribution and stickiness of these accounts were not disclosed.
• Pail container business still incubating: The segment remains in development with many customers in trial and error; the last quarter was "a little bit good" and the company is trying to secure more orders this quarter.
• Value-added products are a margin lever but not a volume one: Niche items like hospital furniture carry better margins but are capital-intensive and not repeat-order business; each hospital buys once.
• Hospital bed exports: Management sees big growth in this segment, is participating in exhibitions abroad, and expects results in coming quarters for both domestic and export orders.
• Product pipeline kept opaque: Small developments are ongoing in blow molding and injection molding, and some value-engineering products are in development, but management declined to name them, saying only that announcements will come "very soon."

Dedhia: "For all the corporates to be very honest the last quarter was not good with our customer factor as well so our customers are like chemical industry, pharma industry, new buying so I think everybody has shrink their margins so, yes, we are trying to get those margins but like it is really, really difficult."

Exports & the Import-Substitution Timeline

• Exports are a plan, not yet a fact: Management confirmed it is planning to start exports "very soon" but gave no date, no target geography, and no product-mix detail.
• The domestic raw material unlock: India is expected to begin manufacturing the compulsory import grade within one year, which would structurally reduce the 40% forced-import dependency and shrink the inventory cycle.
• Exhibition-led demand generation: The company is participating in international exhibitions for hospital furniture, with results expected in coming quarters.

Competitive Position & the Unorganized-Sector Gap

• Pricing opacity: Management acknowledged it does not understand how some competitors sell at lower prices, saying "nobody says the truth, even the customer or the supplier."
• Compliance asymmetry: BIS and EPR requirements apply to organized players but not to unorganized competitors, creating a cost disadvantage that cannot be recovered through pricing when customers are also margin-constrained.
• Capacity utilization as a bright spot: 70%+ utilization was achieved through efficient production planning, cost management, and timely technology investment.

Dedhia: "Some people are selling maybe lower than us, somewhere we also found out that many, many suppliers like us are selling at the lower cost than us, so which we do not understand sometimes the market or the suppliers. I did not know, so sorry I do not have that answer with me right now."

Industry Tailwinds

• Rigid plastic packaging growth: The India market is projected to reach \$18.02 billion by 2027, growing at an 8.01% CAGR.
• Pharma demand: The pharmaceutical market is growing at double digits, directly benefiting the company's core customer vertical.
• Hospital furniture: Demand is bright, driven by new hospital facilities and government focus on medical infrastructure.
• Oil price trend: Softening oil prices from May and June, with the trend still downward compared to a year ago, is positive for plastic packaging input costs.

Guidance & Commitments

Key Metrics